Antengene
As of the edition of 20 October 2026, Antengene runs 5 drugs, 1 of them marketed; it is on route A at 6 targets and on route B at 0 targets.
Sources: ClinicalTrials.gov, FDA Orange Book and Purple Book, other approval registers, company records.
Drugs by status
| Status | Count |
|---|---|
| Marketed | 1 |
| Active | 1 |
| Stopped | 3 |
| Total | 5 |
Marketed drugs and when their US protection ends
| Drug | US protection | Route B rows |
|---|---|---|
| Tislelizumab | Ends 2036 (computed from the first US licence) | 2 |
A route B row is one company at one target.
Where it needs a new molecule
Route A at 6 targets, route B at 0 targets.
All 6 rows on route A or B
In the product6 company-target rows on route A or B; 3 are not shown here, and no score is.
See all 6 targets where Antengene needs a new molecule, with the facts behind eachRequest access. Nothing is shown until you do.
Where its trials are
- Cancer: 5 trials led
- Blood and lymph: 3 trials led
- Immune system: 2 trials led